ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection

Phase 2

Completed

• Conditions: Clostridium Difficile Infection
• Interventions: Drug: Ibezapolstat; Drug: Vancomycin

• Registration Number: NCT04247542
• Lead Sponsor: Acurx Pharmaceuticals Inc.

Brief Summary

Segments 2A and 2B of this trial evaluate the safety, efficacy, pharmacokinetics, fecal concentrations, and fecal microbiome effects of ACX-362E \[ibezapolstat\] in patients with C. difficile infection (CDI).

Detailed Description

This Phase 2, multicenter, open-label single-arm segment (2A) followed by a double-blind, randomized, active-controlled segment (2B) is designed to evaluate ACX-362E in the treatment of CDI. Segment 2A of this trial was an open-label study of up to 20 patients at 6 study centers and was terminated early at 10 patients based on the protocol-specified Trial Oversight Committee's assessment of the compelling efficacy and safety data. Patients were treated with 450 mg of oral ibezapolstat bid for 10 days. In segment 2A all (10 of 10) patients were cured of CDI at end of treatment and all (10 of 10) were sustained clinical cures 30 days after EOT. Ibezapolstat was well tolerated with no reported SAEs. The trial will advance to Segment 2B which is a double-blind comparison of ibezapolstat to the standard of care, oral vancomycin, in approximately 64 subjects (1-1 randomization) at up to approximately 15 sites.

Subjects will be evaluated for cure, safety, and tolerability. All subjects in both segments will have stool samples tested for microbiome profiles. Pharmacokinetic (PK) testing for systemic exposure will be performed on blood samples. Stool samples will be tested for study drug concentration.

Study Timeline

• Study First Submitted: 2020-01-23
• Study First Submitted QC: 2020-01-29
• Study First Posted: 2020-01-30
• Study Start: 2020-03-06
• Primary Completion: 2023-10-03
• Study Completion: 2023-11-15
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-13
• Last Update Posted: 2024-05-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

1. Male or female 18 to 90 years of age, inclusive, at the time of Screening.

2. Capable of reading, understanding, and signing the written informed consent; able to adhere to all study procedures and attend all scheduled study visits.

3. Confirmed diagnosis of mild or moderate CDI as defined by the Infectious Diseases Society of America/Society for Healthcare Epidemiology of America guidelines (McDonald et al. 2018). Subjects will be diagnosed with CDI based on clinical and laboratory findings:

   1. The presence of diarrhea, defined as passage of ≥ 3 UBMs within 24 hours before dosing; an unformed stool is defined as a Type 5, 6, or 7 on the Bristol Stool Chart (Appendix 2)
   2. A stool test result positive for the presence of C. difficile free toxins using tests that detect toxin A/B (and it is prospectively agreed with the Sponsor). The Sponsor will provide a toxin A/B test kit if the site does not have it as part of standard of care test.
   3. Mild or moderate CDI as defined as a white blood cell count of ≤ 15000 cells/mL and a serum creatinine level < 1.5 mg/dL.

Read More

Exclusion Criteria

1. Received more than 24 hours of dosing (> 4 doses) of oral vancomycin for the current episode of CDI before first dose of study drug.

2. Received more than 24 hours of dosing (> 2 doses) of oral fidaxomicin for the current episode of CDI before first dose of study drug.

3. Received more than 24 hours of dosing (> 3 doses) of oral/IV metronidazole for the current episode of CDI before first dose of study drug.

4. Received any other antibacterial therapy for the current CDI episode within 48 hours before the first dose of study drug.

5. Subjects considered treatment failures on prior antibiotics for their current episode of CDI will be excluded.

6. More than 3 episodes of CDI in the previous 12 months or more than 1 prior episode in the last 3 months, excluding the current episode.

7. Severe, complicated, or life-threatening fulminant CDI with evidence of hypotension (systolic blood pressure less than 90 mmHg), septic shock, peritoneal signs or ileus, or toxic megacolon.

8. Elevated liver transaminases (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) greater than 2 times ULN.

9. Active inflammatory bowel disease (Crohn's disease, ulcerative colitis, Irritable Bowel Syndrome with chronic diarrhea).

10. Any other non-C. difficile diarrhea.

11. Active gastroenteritis because of Salmonella, Shigella, Escherichia coli 0157H7, Yersinia or Campylobacter, a parasite, or virus within the past 2 weeks.

12. Had a known positive diagnostic test for other relevant gastrointestinal [GI] pathogens in the 2 weeks before study drug treatment and/or colonization/infection by ova or parasites.

13. Major GI surgery (ie, significant bowel resection) within 3 months of enrollment (does not include appendectomy or cholecystectomy).

14. Prior or current use of anti-C. difficile toxin antibodies.

15. Have received a vaccine against C. difficile or its toxins.

16. Anticipated that systemic antibacterial therapy for a non-CDI infection will be required for > 7 days after start of study therapy.

17. Actively taking anti-diarrheals, and unable to discontinue anti-diarrheal medication, or any medication with the potential to slow bowel movement (for opiates, a stable dose, including use as needed, is permitted).

18. Actively taking Saccharomyces boulardii and unwilling to discontinue during the study period.

19. Received a fecal transplant in the previous 3 months.

20. Received laxatives in the last 48 hours.

21. Unable or unwilling to stop taking oral probiotics for the duration of the study.

22. Received intravenous immunoglobulin within 3 months before study drug treatment.

23. Sepsis.

24. Have a known current history of significantly compromised immune system such as:

    1. Subjects with a known history of human immunodeficiency virus infection and CD4 <200 cells/mm3 within 6 months of start of study therapy.
    2. Severe neutropenia with neutrophil count < 500 cells/mL.
    3. Concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for active malignancy.

25. Pregnant or lactating women.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Ibezapolstat	Ibezapolstat	Active investigational antibacterial agent: ibezapolstat 450 mg po Q12H x 10 days
Vancomycin	Vancomycin	Standard of care: Vancomycin 125 mg po Q6H x 10 days

Primary Outcome Measures

Name	Time	Method
Percentage of patients with adverse events	38 days	Safety
Clinical cure	12 days	Percentage of patients with clinical cure at the test of cure visit

Secondary Outcome Measures

Name	Time	Method
Plasma and fecal concentrations of ACX-362E	10 days	Pharmacokinetics and systemic exposure
Percentage of patients with sustained clinical cure	38 days	Clinical cure at the test of cure visit (ie, at least 48 hours post end of treatment) and no recurrence within 28 days

Trial Locations

Locations (29)

Acurx Site #103: Dr John Pullman; 🇺🇸 Butte, Montana, United States

Acurx Site #114: Dr Eugene Ryan; 🇺🇸 Chattanooga, Tennessee, United States

Acurx Site #121: Dr Ramesh Gowrappala; 🇺🇸 Houston, Texas, United States

Acurx Site #115: Dr Neera Grover; 🇺🇸 Apple Valley, California, United States

Acurx Site #125: Dr Karen Simon; 🇺🇸 Camarillo, California, United States

Acurx Site #111: Dr Jatinder Pruthi; 🇺🇸 Lancaster, California, United States

Acurx Site #131: Dr Michael Jardula; 🇺🇸 Palm Springs, California, United States

Acurx Site #105; 🇺🇸 Doral, Florida, United States

Acurx Site #122: Dr Faride Ramos; 🇺🇸 Doral, Florida, United States

Acurx Site #107: Dr Belkis Delgado; 🇺🇸 Miami Springs, Florida, United States

Acurx Site #124: Dr Yunior Silva-Barrero; 🇺🇸 Miami, Florida, United States

Acurx Site #108: Dr Idania Garcia Del Sol; 🇺🇸 Miami, Florida, United States

Acurx Site #101: Dr Idalia Acosta; 🇺🇸 Miami, Florida, United States

Acurx Site #116: Dr Erick Juarez; 🇺🇸 Miami, Florida, United States

Acurx Site #119: Dr Jorge Paoli-Bruno; 🇺🇸 Miami, Florida, United States

Acurx Site #130: Dr Michael DiGiovanna; 🇺🇸 North Massapequa, New York, United States

Acurx Site #126: Dr Andrew Pearson; 🇺🇸 Myrtle Beach, South Carolina, United States

Acurx Site #120: Dr Vanna Gold; 🇺🇸 Lampasas, Texas, United States

Acurx Site #109: Dr Robert Brennan; 🇺🇸 Lynchburg, Virginia, United States

Acurx Site #113: Dr Jennifer Vincent; 🇺🇸 Temple, Texas, United States

Acurx Site #110: Dr Val Hansen; 🇺🇸 Bountiful, Utah, United States

Acurx Site #106: Dr Bezawit Tekola; 🇺🇸 Fairfax, Virginia, United States

Acurx Site #102: Dr Richard Nathan; 🇺🇸 Idaho Falls, Idaho, United States

Acurx Site #118: Dr Janet Reiser; 🇺🇸 Scottsdale, Arizona, United States

Acurx Site #104: Dr JeanMarie Houghton; 🇺🇸 Worcester, Massachusetts, United States

Acurx Site #123: Dr Harry Schrager; 🇺🇸 Newton, Massachusetts, United States

Acurx Site #117: Dr Rafael Companioni; 🇺🇸 Panama City, Florida, United States

Acurx Site #129: Dr Stuart Cohen; 🇺🇸 Sacramento, California, United States

Acurx Site #127: Dr Christopher Connolley; 🇺🇸 Winston-Salem, North Carolina, United States